<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53169</article-id><article-id pub-id-type="doi">10.7554/eLife.53169</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-165682"><name><surname>Flyak</surname><given-names>Andrew I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-165683"><name><surname>Ruiz</surname><given-names>Stormy E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0892-9626</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165684"><name><surname>Salas</surname><given-names>Jordan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165685"><name><surname>Rho</surname><given-names>Semi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165686"><name><surname>Bailey</surname><given-names>Justin R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-39433"><name><surname>Bjorkman</surname><given-names>Pamela J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2277-3990</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Division of Biology and Biological Engineering</institution>, <institution>California Institute of Technology</institution>, <addr-line><named-content content-type="city">Pasadena</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Medicine</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1309"><name><surname>Li</surname><given-names>Wenhui</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Biological Sciences</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bjorkman@caltech.edu</email> (PB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>03</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e53169</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>02</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Flyak et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Flyak et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53169-v1.pdf"/><abstract><p>A vaccine protective against diverse HCV variants is needed to control the HCV epidemic. Structures of E2 complexes with front layer-specific broadly neutralizing antibodies (bNAbs) isolated from HCV-infected individuals, revealed a disulfide bond-containing CDRH3 that adopts straight (individuals who clear infection) or bent (individuals with chronic infection) conformation. To investigate whether a straight versus bent disulfide bond-containing CDRH3 is specific to particular HCV-infected individuals, we solved a crystal structure of the HCV E2 ectodomain in complex with AR3X, a bNAb with an unusually long CDRH2 that was isolated from the chronically-infected individual from whom the bent CDRH3 bNAbs were derived. The structure revealed that AR3X utilizes both its ultralong CDRH2 and a disulfide motif-containing straight CDRH3 to recognize the E2 front layer. These results demonstrate that both the straight and bent CDRH3 classes of HCV bNAb can be elicited in a single individual, revealing a structural plasticity of <italic>VH1-69</italic>-derived bNAbs.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI127469</award-id><principal-award-recipient><name><surname>Bailey</surname><given-names>Justin R</given-names></name><name><surname>Bjorkman</surname><given-names>Pamela J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000884</institution-id><institution>Cancer Research Institute</institution></institution-wrap></funding-source><award-id>Irvington Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Flyak</surname><given-names>Andrew I</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Andrew I Flyak, A.I.F. and J.R.B. are inventors of International Patent Application, Serial no. PCT/US2019/029315, pertaining to some of the antibodies presented in this article..</p></fn><fn fn-type="conflict" id="conf3"><p>Justin R Bailey, A.I.F. and J.R.B. are inventors of International Patent Application, Serial no. PCT/US2019/029315, pertaining to some of the antibodies presented in this article..</p></fn><fn fn-type="conflict" id="conf4"><p>Pamela J Bjorkman, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Diffraction data have been deposited in PDB under the accession code 6URH.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Flyak AI</collab><collab>Bjorkman PJ</collab></person-group><year iso-8601-date="2020">2020</year><source>Crystal structure of broadly neutralizing antibody AR3X in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6URH">https://www.rcsb.org/structure/6URH</ext-link><comment>Protein Data Bank, 6URH</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-53169-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>